08:31 AM EDT, 05/24/2024 (MT Newswires) -- Exact Sciences ( EXAS ) said Friday it will present 10 abstracts showing its screening and diagnostic portfolio, including new data confirming the predictive and prognostic value of the Oncotype DX Breast Recurrence Score test.
The company said that based on new data from two studies assessing Recurrence Score results, the test predicted breast cancer survival across various racial and ethnic groups.
The 10 abstracts will be presented at the American Society of Clinical Oncology Annual Meeting, May 31 to June 4, in Chicago, the company said.
Shares of Exact Sciences ( EXAS ) were down 6.6% in recent Friday premarket activity.
Price: 50.50, Change: -3.58, Percent Change: -6.62